肿瘤内在机制调控 PD-L1 的临床意义。
Clinical implications of tumor-intrinsic mechanisms regulating PD-L1.
机构信息
Department of Hematology and Oncology, Freiburg University Medical Center, 79106 Freiburg, Germany.
Faculty of Biology, Albert Ludwigs University of Freiburg, 79104 Freiburg, Germany.
出版信息
Sci Transl Med. 2019 Feb 6;11(478). doi: 10.1126/scitranslmed.aav4810.
PMID:30728286
Abstract
Treatment with immune checkpoint inhibitors targeting programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) is effective in many cancer types. Tumors harboring specific mutations modulate antitumor immune responses through the PD-1/PD-L1 axis, and this should be taken into account when designing rational combinatory treatments.
摘要
针对程序性死亡受体-1（PD-1）或程序性死亡配体-1（PD-L1）的免疫检查点抑制剂的治疗在许多癌症类型中是有效的。携带特定突变的肿瘤通过 PD-1/PD-L1 轴调节抗肿瘤免疫反应，在设计合理的联合治疗时应考虑这一点。
Zotero 插件